
|Videos|August 7, 2021
Evaluating risuteganib for dry eye disease treatment
Author(s)David Hutton, Alex Delaney-Gesing
Advertisement
Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island (Garden City, NY), discusses highlights from his presentation of trial results analyzing risuteganib as a potential treatment for dry eye disease.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease
3
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
4
AAO 2025: Diana Do reviews the real-world use of aflibercept 8 mg
5